Articles tagged "Rejection"

2017 American Transplant Congress
Co-Stimulation Blockade to Minimize and Withdraw Long Term Calcineurin Inhibitors (CNI) in Simultaneous Pancreas and Kidney Transplant (SPK).
P. Stock,¹ R. Mannon,² B. Armstrong,³ D. Ikle,³ M. Robian,⁴ Y. Morrison,⁴ J. Odorico,⁵ J. Fridell,⁶ A. Mehta,⁷ K. Newell.⁷
¹UCSF, San Francisco; ²UAB, Birmingham, AL; ³Rho Inc, Chapel Hill, NC; ⁴NIH/NIAID, Bethesda, MD; ⁵UW, Madison, WI; ⁶IU, Indianapolis, IN; ⁷Emory University, Atlanta, GA
The NIH multicenter CTOT-15 trial tested the hypothesis that use of belatacept (bela) could minimize or eliminate long-term CNI use in simultaneous pancreas and kidney…
2017 American Transplant Congress
DSA Presence Does Not Affect Renal Histology and Clinical Outcome in Chronic Active Antibody Mediated Rejection.
K. Sablik,¹ M. Clahsen–van Groningen,¹ C. Looman,¹ J. Damman,¹ D. Roelen,² M. van Agteren,¹ M. Betjes.¹
¹Erasmus MC, Rotterdam, Netherlands; ²Leiden UMC, Leiden, Netherlands
Introduction. Chronic active antibody mediated rejection (caABMR) is a major cause of long term renal allograft dysfunction. It is defined by the presence of microvascular…
2017 American Transplant Congress
Predictive Value of Pre-Transplant Cross-Match Techniques on Living Donor Kidney Transplant Outcomes.
M. Meneghini,¹ E. Melilli,¹ I. Revuelta,³ R. Rajalingam,² E. Rigol,⁴ S. Chandran,² F. Diekmann,³ F. Vincenti,² J. Cruzado,¹ J. Martorell,⁴ O. Bestard.¹
¹Kidney Transplant Unit, Bellvitge University Hospital; IDIBELL, Barcelona, Spain; ²Kidney Transplant Unit, UCSF Medical Centre, SanFrancisco; ³Kidney Transplant Unit, Clinic University Hospital, Barcelona, Spain; ⁴Immunology Department, Clinic University Hospital, Barcelona, Spain
Study aim: To investigate the impact of different cross-match techniques and their combination before living-donor kidney transplantation(LDKT) on main clinical outcomes.Methods: Retrospective study including 394…
2017 American Transplant Congress
Integrative Analysis of ExomeSeq and Gene Expression Data for Identification of Novel Variants Associated with Antibody-Mediated Rejection in Kidney Transplant.
S. Pineda,^1,2 T. Sigdel,² A. Jackson,³ M. Sirota,^1,2 M. Sarwal.²
¹Institute for Computational Health Science, University of California, San Francisco (UCSF), San Francisco, CA; ²Department of Surgery, University of California, San Francisco (UCSF), University of California, San Francisco (UCSF), CA; ³Department of Medicine, Johns Hopkins, Baltimore, MD
Background: The objective of this work is to characterize the impact of the donor-recipient (D/R) HLA and non-HLA mismatches on the risk of antibody-mediated rejection…
2017 American Transplant Congress
Transcript Changes Associated with Graft Rejection Are Not Specific for Rejection Because They Are Shared with Tissue Responses to Wounding.
P. Halloran, K. Famulski, INTERCOMEX Study Group.
University of Alberta, Edmonton, Canada
The diagnosis of rejection by histology is based on the presence of relatively non-specific lesions. This is because the histology lesions are actually non-specific, but…
2017 American Transplant Congress
Triptolide Alleviating Acute Antibody Mediated Rejection by Inhibition of B Cell Activation in Presensitized Recipients.
D. Zhao,¹ S. Li,¹ T. Liao,¹ Y. Wei,² X. Hua,¹ F. Han,¹ Z. Luo,¹ X. Liu,¹ Q. Sun.
¹Kidney Transplantation, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China; ²Key Laboratory of Gene Engineering of the Ministry of Education, State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, Guangdong, China
Backgroud: Acute antibody mediated rejection (AMR), resistant to most anti-rejection therapy, is main cause for renal graft loss. Triptolide(TPL) had been reported as a promising…
2017 American Transplant Congress
Post-Transplant Lymphoproliferative Disorder: Risk Analysis for Pancreas Transplant Patients.
E. Minja, T. Dunn, A. Matas, T. Pruett, R. Kandaswamy, E. Finger.
Dept of Surgery, University of Minnesota, Minneapolis, MN
Objective: Determine incidence, risk factors, and impact of PTLD in pancreas transplantation (PTx).Methods: Retrospective review of all PTx performed between 7/25/1978 and 12/17/2015 at a…
2017 American Transplant Congress
Conversion from Tacrolimus-Based to Everolimus-Based Immunosuppressive Therapy 3 Months After Living-Donor Kidney Transplantation: A Randomized-Controlled Clinical Trial.
D. Hesselink,¹ N. Shuker,¹ J. Osinga,¹ M. Clahsen -van Groningen,² J. Damman,² C. Baan,¹ J. van de Wetering,¹ A. Rowshani,¹ J. Kal -van Gestel,¹ W. Weimar,¹ T. van Gelder,³ R. Bouamar.³
¹Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ²Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands; ³Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
While conversion from ciclosporin to everolimus is well documented, conversion from tacrolimus has been poorly studied. In this randomized-controlled trial the safety and tolerability of…
2017 American Transplant Congress
Long Term Outcomes of Adult Kidney Transplants from Small Single Pediatric Donors Are Equivalent to Standard Criteria Donors.
R. McMillan, K. Gray, T. Khader, A. Jabri, J. Kim, A. Watkins.
Surgery, Weill Cornell Medicine, New York, NY
PurposeWe analyzed long term outcomes of adult kidney transplant recipients from single pediatric donors at a large volume center.MethodsA retrospective review of 90 adult kidney…
2017 American Transplant Congress
Predicting Immunologic Risk for Acute Rejection in Pediatric Liver Transplantation.
S. Antala, L. Bow, R. Morotti, G. Gan, D. Yanhong, U. Ekong, S. Emre.
Yale University, New Haven, CT
Background: Studies in heart, lung, kidney, & liver transplantation (LT) indicate an increased negative impact of antibodies (Ab) to HLA on allograft outcome.Aim: To describe…